{
    "id": "dbpedia_5068_3",
    "rank": 7,
    "data": {
        "url": "https://www.linkedin.com/posts/pink-hope-charity_hereditary-cancer-survey-activity-7196268046611615744-j1j6",
        "read_more_link": "",
        "language": "en",
        "title": "Pink Hope on LinkedIn: Hereditary Cancer Survey",
        "top_image": "https://media.licdn.com/dms/image/sync/v2/D5627AQG0CKDW6LnGog/articleshare-shrink_800/articleshare-shrink_800/0/1715673895866?e=2147483647&v=beta&t=ozTpvmFClE3l9ES3IlwSO4zPU96MyqLkvucv2AZqEh0",
        "meta_img": "https://media.licdn.com/dms/image/sync/v2/D5627AQG0CKDW6LnGog/articleshare-shrink_800/articleshare-shrink_800/0/1715673895866?e=2147483647&v=beta&t=ozTpvmFClE3l9ES3IlwSO4zPU96MyqLkvucv2AZqEh0",
        "images": [
            "https://media.licdn.com/dms/image/C563DAQHRCI_2Cg81Dg/image-scale_191_1128/0/1680467391829/pink_hope_charity_cover?e=2147483647&v=beta&t=hswwiKfagAjD4Xd1F2zb0yP4f-8F4U2l0IEBgPfILRI"
        ],
        "movies": [],
        "keywords": [],
        "meta_keywords": [
            ""
        ],
        "tags": null,
        "authors": [
            "Pink Hope"
        ],
        "publish_date": "2024-05-14T22:00:02.466000+00:00",
        "summary": "",
        "meta_description": "Your experience matters: take our Hereditary Cancer Survey! \n\nWe are conducting a national survey to understand the experience and challenges of our community‚Ä¶",
        "meta_lang": "en",
        "meta_favicon": "https://static.licdn.com/aero-v1/sc/h/al2o9zrvru7aqj8e1x2rzsrca",
        "meta_site_name": "",
        "canonical_link": "https://www.linkedin.com/posts/pink-hope-charity_hereditary-cancer-survey-activity-7196268046611615744-j1j6",
        "text": "Did you know the Medicare numbers for prophylactic surgeries related to breast and ovarian cancer risk are the same as those used when patients have surgery after a cancer diagnosis? Eg. if you have your ovaries removed for risk reduction or ovaries removed after an ovarian cancer diagnosis - the same Medicare number is used. Same for mastectomy. So it's really hard to find data for patients who are having risk reduction surgeries. This is one of the reasons we are collecting data from the hereditary cancer community. We want to get a National picture of the experiences and decisions people in our community are making so we can tailor our support, education and resources better. With information and data, we can advocate for changes and improvements for those with hereditary cancer risk. Please encourage your patients/friends/family members to complete this important survey. Every experience is different and we want to hear about all of them. #hereditarycancer #BRCA #PALB2 #CHEK2 #RAD51C #ATM #familycancerhistory #Lynchsyndrome #pinkhopeaus Sarah Powell\n\nYesterday, our collaborators from The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust presented groundbreaking data at #ASCO24. In a study of 78 patients with breast cancer (23 TNBC, 35 HER2+, 18 HR+ and 2 unknown), our ultra-sensitive NeXT Personal¬Æ assay found that 100% of patients with undetectable residual disease in repeat testing did not have cancer recurrence. ctDNA detection correctly identified disease recurrence with a 15-month median lead time in all 14 patients that relapsed. NeXT Personal demonstrated 100% sensitivity and specificity across repeat testing. Learn more: https://bit.ly/4bZJHeY #PrecisionOncology #BreastCancer #LiquidBiopsy #ctDNA #MRD #UltraSensitivityMatters\n\nDid you know it‚Äòs not just women who can be diagnosed with breast cancer? Breast cancer in men is unusual, but men with a BRCA mutation have as high as a one in 20 chance of developing breast cancer. Because of this, men with BRCA variants should perform breast self-exams every month starting at age 35 and should discuss their family history with their doctor. Men with a family history of breast cancer should consider Hereditary Cancer Risk Screening to help detect BRCA mutations. Men who have a BRCA1/2 inherited gene mutation can also have an increased risk of prostate cancer. üîó Learn more about Hereditary Cancer Risk Screening here: https://ow.ly/34n150Q0PLG #BreastCancerAwareness #EarlyDetectionSavesLives #BreastCancerSupport\n\n‚ùó#DYK It‚Äòs not just women who can be diagnosed with breast cancer. Breast cancer in men is unusual, but men with a BRCA mutation have as high as a one in 20 chance of developing breast cancer. Because of this, men with BRCA variants should perform breast self-exams every month starting at age 35 and should discuss their family history with their doctor. Men with a family history of breast cancer should consider Hereditary Cancer Risk Screening to help detect BRCA mutations. Men who have a BRCA1/2 inherited gene mutation can also have an increased risk of prostate cancer. üîó Learn more about Hereditary Cancer Risk Screening here: https://ow.ly/YCLa50Q0Pun #BreastCancerAwareness #EarlyDetectionSavesLives #BreastCancerSupport\n\nWhat is the Biggest Difference Between Standard Genetic Testing and Tumor DNA Sequencing üß¨? Watch here ‚û°Ô∏èhttps://lnkd.in/gjTTYnAM In this short video, Michelle Morand ‚Äì Precision Cancer Medicine Advocacy specialist ‚Äì explains the main difference between standard genetic testing and tumor DNA sequencing‚Ä¶ ‚Ä¶And why all patients should be getting comprehensive sequencing done if they want to access the most effective treatment for their cancer. Want more advocacy tips and direct guidance on cancer care? Join our new free online advocacy program, Cancer: Just the Facts ‚ù§Ô∏è https://lnkd.in/gd9pMpNd And get all your cancer care questions answered, by experts! ü©∫ #CancerJustTheFacts\n\nIn our latest blog post, the Jedi Cancer Foundation explores the groundbreaking realm of single-cell research and its transformative impact on rare cancer prognosis. This area of study holds immense potential, not just in understanding the intricacies of individual cancer cells but also in charting the course for future treatments. A standout quote from the article beautifully encapsulates this hope: ‚ÄúSingle-cell research has the potential to revolutionize cancer research, particularly for rare cancer patients. By studying a single cell, researchers can observe its unique characteristics, such as genetic mutations and other biomarkers, that may distinguish it from other cancers.‚Äù Delve into the details and stay informed about the strides being made in the fight against rare cancers: https://lnkd.in/gUyUV_4z We encourage you to read, reflect, and share this piece. By staying informed, we strengthen our collective resolve and empower our community to continue pushing the boundaries. #RareCancerResearch #SingleCellResearch #RareCancerWarriors #JediRareCancerFoundation #rarecancerisntrare #rarecancertreatment #donatetoday\n\nüéó Breast Cancer Statistics: A Global Perspective üåç Did you know? ü§îThe top ten countries for breast cancer rates are 90% European. Shockingly, when it comes to breast cancer deaths, the stats are 100% non-European, with 4 of the 10, including the top spot, being Caribbean.üìâ This disparity highlights the urgent need for specialized research to understand the genetic factors that impact this demographic, specifically in the Caribbean. At CariGenetics, we're committed to bridging this gap. üî¨Our ongoing research delves deep into the unique genetic makeup of individuals of Caribbean descent to better diagnose, prevent, and treat breast cancer more effectively.üß¨ Join us in this crucial mission. Together, we can shed light on these disparities and work towards a healthier future for everyone!üí™üèæ #BreastCancerStatistics #BreastCancerDeathRate #CaribbeanAncestry #CariGeneticsResearch #CaribbeanCancerResearch #CariGenetics #BreastCancerResearch #CaribbeanCancerResearch #Didyouknow #Bermuda #breastcancerawarenessmonth #cancerresearch #breastcancerresearch #caribbeanwomen\n\nBack in November, the GCI hosted a seminar on \"Knowledge Mobilization to Extend the Impact and Access of Evidence-Based Gynecologic Cancer Interventions in BC\" at the BC Cancer Summit 2023. With incredible speakers from across Canada and North America, the session highlighted several of the most promising #gynecologiccancer interventions to date. The session used a #knowledgemobilization lens to ignite engaging conversations regarding existing barriers to access and implementation, and how collaborative work can be used to overcome them. These interventions include: üíú Cervical Cancer Self-Collection üíú Molecular Stratification for Endometrial Cancer üíú Identification and Stratification of Vulvar Cancer Pre-cancerous and Invasive Lesions üíú Opportunistic Salpingectomy üíú Genetic Testing for Ovarian and Endometrial Cancer Learn more about these interventions and future directions through our GCI seminar recap article below! - #gynecologiccancer #gynecancer #interventions #cancerintervention #ovariancancer #endometrialcancer #uterinecancer #vulvarcancer #vaginalcancer #cervicalcancer #hpvtest #cancerprevention #cancerrisk #bisalp #opportunisticsalpingectomy #womenshealth #bccancer\n\nWorldwide, lung cancer is the leading cause of cancer diagnosis and death, accounting for 2 million diagnoses and 1.8 million deaths. 85% of these are due to non-small cell lung cancer. Yet despite these grim statistics, non-small cell lung cancer is the cancer in which precision medicine has had the biggest impact so far, and there are more than 25 FDA-approved non-small cell lung cancer treatments that target genomic mutations across 11 different genes. But the reality is that despite the availability of these new life-saving therapies, they aren‚Äôt universally reaching the patients who need them. As this Opinion piece in the New York Time articulates, \"A Revolution in Medicine Is Coming. Who Will It Leave Out?\" https://hubs.ly/Q01-BYHT0 #genomics4all #NSCLC #biomarkertesting #precisionmedicine #cancer"
    }
}